HARBIN, China, June 18 /Xinhua-PRNewswire-FirstCall/ -- China Sky OneMedical, Inc. (Amex: CSY) (''China Sky One'' or ''the Company''), a China-basedmanufacturer, marketer and distributor of pharmaceutical, medicinal anddiagnostic kit products, announced today that it has obtained approval fromthe State Food and Drug Administration (SFDA) in the People's Republic ofChina for four new drugs: Tobramycin Eye Drops, Compound Zinc Sulfate EyeDrops, Ofloxacin Suppositories and Ofloxacin Gels.

Tobramycin Eye Drops have been approved for the treatment of acuteinfection on eyelids. Compound Zinc Sulfate Eye Drops have been approved forthe treatment of acute and chronic conjunctivitis and trachoma. OfloxacinSuppositories have been approved for the treatment for bactericidal colpitis,and Ofloxacin Gels have been approved for the treatment for bactericidalinjection. The Company estimates the size of the each market at approximately$ 2 million USD to $2.4 million USD

The new approvals bring the total number of China Sky One's externallyused products to 53 and its total marketed products to 102, giving the Companyone of the most comprehensive pharmaceutical product portfolios in China.China Sky One is still aggressively seeking approval for other drugs withlarge market potential. By the end of 2008, the Company will have a total 34new drugs submitted to the SFDA for approval.

''These four products in China have an extensive market and China Sky Oneexpects to be able to quickly launch them and expand market share through ourextensive sales network and experienced management team,'' said Mr. Yan-qingLiu, Chairman, CEO and President of China Sky One Medical, Inc. ''Goingforward, we are optimistic that these new drugs will provide steady revenuesfor China Sky One and improve our profitability.''

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a China basedcompany engaged in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic kit products. Through itswholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and TechnologyCompany and Harbin First Bio-Engineering Company Limited the Companymanufactures and distributes over-the-counter pharmaceutical products as itsprimary revenue source.